Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Other solid neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Sarcoma 4Ovarian Neoplasms 3Neoplasms 3Endometrial Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Fallopian Tube Neoplasms 2Carcinosarcoma 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Testicular Neoplasms 1Teratoma, Testicular 1Teratoma, Ovarian 1Teratoma 1Stomach Neoplasms 1Stage IA Uterine Sarcoma 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Recurrence 1Platinum-Refractory Fallopian Tube Carcinoma 1Oropharyngeal Neoplasms 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Mouth Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1

Interventions

Taxes 1Immunoglobulin G 1Disulfides 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cervical Adenocarcinoma × Taxes × Sarcoma × Clear all
NCT02020707 2024-07-26

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Mayo Clinic

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryGynecologicOther solid neoplasmSarcoma

Cervical Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡